Celldex Therapeutics (CLDX) takes a hit in the post session after releasing mixed preliminary...

|About: Celldex Therapeutics, Inc (CLDX)|By:, SA News Editor

Celldex Therapeutics (CLDX) takes a hit in the post session after releasing mixed preliminary results from randomized Phase 2b tests of CDX-011 antibody drug conjugate in patients with advanced, heavily pretreated breast cancer. Shares -8.5% AH.